| Objective: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)are two essential angiogenic growth factors, not only having important physiologic function, but also playing critical roles in solid tumor development and metastasis. VEGF can promote proliferation, split and migration of vascular endothelial cells (VEC); improve permeability of microvessel and increase permeability of tumor vessel to plasma proteins; have function on near VEC by paracrine. BFGF is distributed over living body and can give tumor cell protection because it can promote epidermis endothelial cell to reproduce and promote to split, can stimulate vascular endothelial cells converting tumor cell and becoming tube structure, can inhibit NK cell to adhere to tumor cell. In recent year the function of VEGF and bFGF in hemic malignancies become more and more important and lots of studies showed VEGF, bFGF have closed relationship with leukemia. We detected concentration of serum VEGF and bFGF in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and healthy control and concentration of VEGF of bone marrowmonocyte cell culture supernatant in AML and healthy control by emzyme linked immuno-sorbent assay ( ELISA). In the same time we detected some clinical chemical examination and analyzed them with statistic. Our objectives is to study if VEGF and bFGF have over expression in leukemia , discuss the possibility of VEGF and bFGF as predictor of outcome in leukemia and try to find simple, depended indices for clinical diagnose and therapy.Methods: Pretreatment serum VEGF and bFGF concentration were measured in peripheral blood serum obtained from 30 patients with newly diagnosed AML, 26 patients with newly diagnosed ALL and 16 healthy controls ; VEGF concentration of marrow monocyte cell culture supernatant in AML and healthy control also was measured in 28 AML patients and 20 healthy controls. All data were analyzed by SPSS10.0. P Values less than 0.05 were considered to be statistically significant.Results: 1.The comparison of serum VEGF and bFGF concentration in AML , ALL patients and healthy control (1)Serum VEGF(s-VEGF) levels were elevated in AML patients(275.22±229.69pg/ml) compared to control healthy(121.13±104.62pg/ml) (p<0.01); Serum bFGF(s-bFGF) levels were elevated in AML patients(15.89±14.20pg/ml), compared to control healthy(8.15±7.66pg/ml) (p<0.05).(2)S-VEGF levels were (248.73 ±245.17)pg/ml in ALL patients, significantly higher thanhealthy controls (121.13±104.62pg/ml) (p<0.01); S-bFGF levels were (15.48±12.83)pg/ml in ALL patients, significantly higher than healthy controls (8.15±7.66pg/ml) (p<0.05)。2.The comparison between s-VEGF and bFGF concentration in AML , ALL patients pre- and post- treatment.(1)We divided AML patients into two groups(completely release CR and no completely release NR) depended on the reaction on first chemical therapy and found s-VEGF levels(248.73±245.17pg/ml )of pretreatment patients in CR group were lower significantly than in NR(485.08±271.38pg/ml)(P<0.05); s-bFGF levels(15.64±13.54pg/ml)of pretreatment patients in CR group were lower significantly than in NR(16.71±17.36)pg/ml), But it is not statistically significant(P>0.05).(2) We found s-VEGF levels(184.09±193.55pg/ml)of pretreatment patients in CR group were lower significantly than in NR(520.23±272.59pg/ml)(P<0.05); s-bFGF levels(12.01±10.13pg/ml)of pretreatment patients in CR group were lower significantly than in NR(30.41±13.68pg/ml) (P<0.01).3. The comparison between VEGF concentration of marrow monocyte cell culture supernatant in AML and healthy controls ; The comparison between pre -and post -treatment in AML patients; The relationship between VEGF concentration and other chemical examinations: (1) VEGF levels in culture supernatant of marrow monocyte cell cultured 72 hours were (425.31±167.27)pg/ml, significantlyhigher than healthy controls( 140.12±75.13pg/ml) (P<0.001).(2) We divided AML patients into t... |
PDF Full Text Request